CENTER FOR PHARMACOECONOMICS
A division of MEDACorp
Evaluating and Communicating the Societal Impact of Innovations
Receive Our UpdatesAssessing the impact of healthcare innovations on patients, caregivers, the health system, and society.
The Leerink Center for Pharmacoeconomics (CPE) intends to be the storyteller of healthcare innovation. We conduct evaluations to help society understand the long-term societal impact of healthcare innovations. Answering calls from academic experts and professional health economic societies, we estimate the impact an innovation might have on patients, caregivers, the health system, and society as a whole.
Through our commentaries and educational resources, we want to be a catalyst for change. We hope to shape a future where societal outcomes are improved, and the impacts of innovation are celebrated. And in our podcast, we want to share the stories of the people within the industry, including patients, researchers, innovators, and investors.
More About CPE
In an era where healthcare costs are under intense scrutiny, the need to understand the value of pharmaceutical innovation is crucial. CPE specializes in educating, evaluating, and advising on the societal impacts of healthcare innovation. Our approach considers not only the healthcare costs and health benefits of a treatment, but also its impact on society.
-
What We Do
Educate the Industry: We provide commentary and curate resources on debates and themes within pharmacoeconomics to shape a future where healthcare innovations are celebrated and societal outcomes are prioritized.
Evaluate Healthcare Innovation: We conduct evaluations of in-development and approved healthcare treatments using innovative methods that account for the broader societal impacts of healthcare treatments to foster healthcare innovation and improve societal outcomes.
Engage Stakeholders: We provide a platform to share the stories and hear the perspectives of the people within the industry, including patients, researchers, innovators, and investors.
Leerink Center for Pharmacoeconomics Leadership
Melanie (Mel) Whittington is a Managing Director and Head of the Center for Pharmacoeconomics at Leerink Partners, where she leads efforts to demonstrate the societal impacts of healthcare treatments in the United States. As a thought leader in health economics, Dr. Whittington develops cost-effectiveness analyses of both in-development and approved pharmaceuticals from a societal perspective and offers guidance on key components and novel methodologies.
Prior to joining MEDACorp in 2024, Dr. Whittington was the Managing Director and Founder of Valusphere, a health economic consultancy that developed economic evaluations, advised on value demonstration, and provided training to value assessment stakeholders. Prior to Valusphere, Dr. Whittington was the Director of Health Economics at the Institute for Clinical and Economic Review, where she led the design and development of economic evaluations, and was faculty within the School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. Dr. Whittington is a Senior Fellow within the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center and has published more than 70 articles.
Dr. Whittington earned a BS in Biological Sciences from the University of Missouri, an MS in Health Sciences from Western Illinois University, and a PhD in Health Services Research from the University of Colorado Anschutz Medical Campus.
